Navigation Links
Cephalon Conference Call Invitation
Date:5/5/2008

Tuesday, May 6, 2008, 5:30 p.m. U.S. EDT

FRAZER, Pa., May 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced plans to host an investor conference call at 5:30 p.m. EDT on May 6, 2008 to discuss the U.S. Food and Drug Administration advisory committee panel meeting held that day. The advisory committee panel is considering the company's supplemental New Drug Application for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain.

May 6, 2008 Schedule

5:20 p.m. EDT To participate in the conference call, dial 913-312-0407

and refer to Conference Code Number 2046179

5:30 p.m. EDT Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information" then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, May 20, 2008. To listen to the audio replay, dial 719- 457-0820 and use the Conference Code Number 2046179.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cephalon Reports Strong First Quarter Earnings
2. Cephalon Appoints Gerald J. Pappert as General Counsel
3. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
4. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
5. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
7. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
8. United American Healthcare Corporation to Host Fiscal 2008 Third Quarter Results Conference Call May 13th
9. Digirad Corporation to Present at Bank of America 2008 Health Care Conference
10. Zimmer Holdings to Present at Deutsche Bank 33rd Annual Health Care Conference
11. American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... New York, NY (PRWEB) , ... December 07, ... ... measurable amounts of the drug in their bodies, a researcher at the Icahn ... the journal Pediatric Research. , The study found that when young children are ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... EnghouseSystems ... purchase price of approximately $17.4 million (net of the cash acquired), subject ... $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward Hallowell, ... on social media that offer a rare glimpse into the mind of those people ... New York Times bestselling author, has described people with ADHD as having “Ferrari engines ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... -- Research and Markets has announced the addition of ... Forecast to 2021" report to their offering. ... , , The immunohistochemistry ... at a CAGR of 7.3% during the forecast period of 2016 to ... and rapidly increasing geriatric population across the globe are the primary driving ...
(Date:12/7/2016)... , Dec. 7, 2016  Palatin Technologies, Inc. ... closed on a previously disclosed underwritten public offering ... Genuity acted as sole book-running manager, Roth Capital ... Markets acted as co-manager for the offering. ... million in net proceeds, allowing us to continue ...
Breaking Medicine Technology: